Primary objective :
- To compare disease-free survival after treatment with docetaxel in combination with
doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by
docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive
axillary lymph nodes.
Secondary objectives :
- To compare toxicity and quality of life between the 2 above-mentioned arms.
- To evaluate pathologic and molecular markers for predicting efficacy.